BACKGROUND AND PURPOSE: C5a, a complement activation product, exhibits a broad spectrum of inflammatory activities particularly neutrophil chemoattraction. Herein, the role of C5a in the genesis of inflammatory hypernociception was investigated in rats and mice using the specific C5a receptor antagonist PMX53 (AcF-[OP(D-Cha)WR]). EXPERIMENTAL APPROACH: Mechanical hypernociception was evaluated with a modification of the Randall-Selitto test in rats and electronic pressure meter paw test in mice. Cytokines were measured by ELISA and neutrophil migration was determined by myeloperoxidase activity. KEY RESULTS: Local pretreatment of rats with PMX53 (60-180 microg per paw) inhibited zymosan-, carrageenan-, lipopolysaccharide (LPS)- and antigen-induced hypernociception. These effects were associated with C5a receptor blockade since PMX53 also inhibited the hypernociception induced by zymosan-activated serum and C5a but not by the direct-acting hypernociceptive mediators, prostaglandin E(2) and dopamine. Underlying the C5a hypernociceptive mechanisms, PMX53 did not alter the cytokine release induced by inflammatory stimuli. However, PMX53 inhibited cytokine-induced hypernociception. PMX53 also inhibited the recruitment of neutrophils induced by zymosan but not by carrageenan or LPS, indicating an involvement of neutrophils in the hypernociceptive effect of C5a. Furthermore, the C5a-induced hypernociception was reduced in neutrophil-depleted rats. Extending these findings in rats, blocking C5a receptors also reduced zymosan-induced joint hypernociception in mice. CONCLUSIONS AND IMPLICATIONS: These results suggest that C5a is an important inflammatory hypernociceptive mediator, acting by a mechanism independent of hypernociceptive cytokine release, but dependent on the presence of neutrophils. Therefore, we suggest that inhibiting the action of C5a has therapeutic potential in the control of inflammatory pain.
BACKGROUND AND PURPOSE:C5a, a complement activation product, exhibits a broad spectrum of inflammatory activities particularly neutrophil chemoattraction. Herein, the role of C5a in the genesis of inflammatory hypernociception was investigated in rats and mice using the specific C5a receptor antagonist PMX53 (AcF-[OP(D-Cha)WR]). EXPERIMENTAL APPROACH: Mechanical hypernociception was evaluated with a modification of the Randall-Selitto test in rats and electronic pressure meter paw test in mice. Cytokines were measured by ELISA and neutrophil migration was determined by myeloperoxidase activity. KEY RESULTS: Local pretreatment of rats with PMX53 (60-180 microg per paw) inhibited zymosan-, carrageenan-, lipopolysaccharide (LPS)- and antigen-induced hypernociception. These effects were associated with C5a receptor blockade since PMX53 also inhibited the hypernociception induced by zymosan-activated serum and C5a but not by the direct-acting hypernociceptive mediators, prostaglandin E(2) and dopamine. Underlying the C5a hypernociceptive mechanisms, PMX53 did not alter the cytokine release induced by inflammatory stimuli. However, PMX53 inhibited cytokine-induced hypernociception. PMX53 also inhibited the recruitment of neutrophils induced by zymosan but not by carrageenan or LPS, indicating an involvement of neutrophils in the hypernociceptive effect of C5a. Furthermore, the C5a-induced hypernociception was reduced in neutrophil-depleted rats. Extending these findings in rats, blocking C5a receptors also reduced zymosan-induced joint hypernociception in mice. CONCLUSIONS AND IMPLICATIONS: These results suggest that C5a is an important inflammatory hypernociceptive mediator, acting by a mechanism independent of hypernociceptive cytokine release, but dependent on the presence of neutrophils. Therefore, we suggest that inhibiting the action of C5a has therapeutic potential in the control of inflammatory pain.
Authors: Francisco Airton Castro da Rocha; Mauro Martins Teixeira; José Carlos da Silva Rocha; Virgínia Cláudia Carneiro Girão; Mirna Marques Bezerra; Ronaldo de Albuquerque Ribeiro; Fernando de Queiroz Cunha Journal: Eur J Pharmacol Date: 2004-08-16 Impact factor: 4.432
Authors: Trent M Woodruff; Thiruma V Arumugam; Ian A Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor Journal: J Immunol Date: 2003-11-15 Impact factor: 5.422
Authors: Darren R March; Lavinia M Proctor; Martin J Stoermer; Robert Sbaglia; Giovanni Abbenante; Robert C Reid; Trent M Woodruff; Khemar Wadi; Natalii Paczkowski; Joel D A Tyndall; Stephen M Taylor; David P Fairlie Journal: Mol Pharmacol Date: 2004-04 Impact factor: 4.436
Authors: John M Dawes; Margarita Calvo; James R Perkins; Kathryn J Paterson; Hannes Kiesewetter; Carl Hobbs; Timothy K Y Kaan; Christine Orengo; David L H Bennett; Stephen B McMahon Journal: Sci Transl Med Date: 2011-07-06 Impact factor: 17.956
Authors: Alessio Moriconi; Thiago M Cunha; Guilherme R Souza; Alexandre H Lopes; Fernando Q Cunha; Victor L Carneiro; Larissa G Pinto; Laura Brandolini; Andrea Aramini; Cinzia Bizzarri; Gianluca Bianchini; Andrea R Beccari; Marco Fanton; Agostino Bruno; Gabriele Costantino; Riccardo Bertini; Emanuela Galliera; Massimo Locati; Sérgio H Ferreira; Mauro M Teixeira; Marcello Allegretti Journal: Proc Natl Acad Sci U S A Date: 2014-11-10 Impact factor: 11.205
Authors: Waldiceu A Verri; Thiago M Cunha; Danilo A Magro; Ana T G Guerrero; Silvio M Vieira; Vanessa Carregaro; Guilherme R Souza; Maria das Graças M O Henriques; Sérgio H Ferreira; Fernando Q Cunha Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-10-15 Impact factor: 3.000
Authors: D A Valério; F I Ferreira; T M Cunha; J C Alves-Filho; F O Lima; J R De Oliveira; S H Ferreira; F Q Cunha; R H Queiroz; W A Verri Journal: Br J Pharmacol Date: 2009-07-23 Impact factor: 8.739
Authors: Leonid P Shutov; Charles A Warwick; Xiaoyu Shi; Aswini Gnanasekaran; Andrew J Shepherd; Durga P Mohapatra; Trent M Woodruff; J David Clark; Yuriy M Usachev Journal: J Neurosci Date: 2016-05-04 Impact factor: 6.167
Authors: Karla G G Serafim; Suelen A Navarro; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Victor Fattori; Thiago M Cunha; Jose C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-08-06 Impact factor: 3.000